CMMB - Chemomab Therapeutics - ADR GAAP EPS of -$0.04 beats by $0.19
- Chemomab Therapeutics - ADR press release ( NASDAQ: CMMB ): Q3 GAAP EPS of -$0.04 beats by $0.19 .
- Cash and cash equivalents were $46.5M as of September 30, 2022, compared to $51.8M as of June 30, 2022.
- The company currently expects its runway to last through year-end 2023.
For further details see:
Chemomab Therapeutics - ADR GAAP EPS of -$0.04 beats by $0.19